Active Biotech AB Interim Report January – September 2011

* Laquinimod - Phase III BRAVO trial concluded. Teva plans an additional
    clinical study before filing a registration application in the US
  * TASQ - enrolment of patients for Phase III trial ongoing
  * TASQ -  Phase II trial published in Journal of Clinical Oncology
  * ANYARA - Phase III trial proceeding according to plan
  * 57-57 - a clinical trial in  being prepared in systemic sclerosis
  * ISI - project is proceeding as planned
  * RhuDex® - preparations for continued clinical development ongoing
  * Net sales  SEK 231.3 M (8.5)
  * Operating loss SEK 6.2 M (loss: 149.7)
  * Loss after tax SEK 1.3 M (loss: 156,8)
  * Loss per share for the period amounted to SEK 0,02 (loss: 2.40)

For further information, please contact:

Tomas Leanderson
President and CEO
Tel +46 (0)46-19 20 95

Hans Kolam, CFO
Tel: +46 (0)46-19 20 44

Active Biotech AB (Corp. Reg. No. 556223-9227)
PO Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00
Fax: +46 (0) 46-19 11 00

This report is also available at www.activebiotech.com




Active Biotech AB Interim Report Jan-Sep 2011:
http://hugin.info/1002/R/1560312/482696pdf




This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
    other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
     originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE

[HUG#1560312]